Amphotericin B-induced immunosuppression in tumor-bearing mice.
B16 melanoma-bearing mice had a reduced capacity to mount a delayed-type hypersensitivity response, and this response was further depressed when these mice were also treated with multiple daily doses of amphotericin B (AmB). Results from the present experiments, which were designed to simulate the clinical situation, indicate that patients receiving AmB may require frequent monitoring of immune functions during treatment.